ASCO 2022: Breast cancer highlights
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
ASCO 2022: Breast cancer highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
6 Jun 2022
Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer
Dr Etienne Brain - Institut Curie, Paris, France
Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer ( Dr Etienne Brain - Institut Curie, Paris, France )
6 Jun 2022
Safety follow-up of the randomized, phase 3 study DESTINY-Breast03
Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA
Safety follow-up of the randomized, phase 3 study DESTINY-Breast03 ( Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA )
5 Jun 2022
Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 exp...
Dr Shanu Modi - Memorial Sloan Kettering Cancer Centre, Manhattan, USA
Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expression ( Dr Shanu Modi - Memorial Sloan Kettering Cancer Centre,  Manhattan, USA )
5 Jun 2022
Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic b...
Dr Jane Lowe Meisel- Winship Cancer Institute of Emory University, Georgia, USA
Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients ( Dr Jane Lowe Meisel- Winship Cancer Institute of Emory University, Georgia, USA )
5 Jun 2022
Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast can...
Shanu Modi- Memorial Sloan Ketting Cancer Center, Manhattan, USA
Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients ( Shanu Modi- Memorial Sloan Ketting Cancer Center, Manhattan, USA )
5 Jun 2022
Sacituzumab goviteca provides clinically meaningful PFS benefit for hormone rece...
Dr Hope Rugo - University of California San Francisco, San Francisco, USA
Sacituzumab goviteca provides clinically meaningful PFS benefit for hormone receptor HR+/HER2‐ advanced breast cancer patients ( Dr Hope Rugo - University of California San Francisco, San Francisco, USA )
4 Jun 2022
Comment: Sacituzumab govitecan for HR+/HER2‐ advanced breast cancer
Dr Jane Lowe Meisel - Winship Cancer Institute of Emory University, Georgia, USA
Comment: Sacituzumab govitecan for HR+/HER2‐ advanced breast cancer ( Dr Jane Lowe Meisel - Winship Cancer Institute of Emory University, Georgia, USA )
4 Jun 2022
Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer
Dr Hope Rugo - University of California San Francisco, San Francisco, USA
Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer ( Dr Hope Rugo - University of California San Francisco, San Francisco, USA )
4 Jun 2022
Cancer Services Delivery: Focus on India
Dr Soumitra Datta - Tata Medical Center, Kolkata, India
Cancer Services Delivery: Focus on India ( Dr Soumitra Datta - Tata Medical Center, Kolkata, India )
26 May 2022
Diagnostic performance and survival outcome of SLNB procedure in breast cancer p...
Dr Sanjit Kumar Agrawal - Tata Medical Center, Kolkata, India
Diagnostic performance and survival outcome of SLNB procedure in breast cancer patients from a tertiary cancer care centre ( Dr Sanjit Kumar Agrawal - Tata Medical Center, Kolkata, India )
25 May 2022
War in Ukraine: Impacts on the Ukrainian cancer care system
Dr Andriy Hrynkiv - Lviv Regional Cancer Centre of Ukraine, Lviv, Ukraine
War in Ukraine: Impacts on the Ukrainian cancer care system ( Dr Andriy Hrynkiv - Lviv Regional Cancer Centre of Ukraine, Lviv, Ukraine )
4 May 2022